Skip to main content
. 2021 Aug 19;51(10):2513–2521. doi: 10.1002/eji.202049107

Figure 3.

Figure 3

Characteristics of DKO gene‐edited CAR T‐19 cells. (A) DKO gene‐edited CAR T‐19 cells were produced and cultured for 10 days before being used in subsequent assays. (B) Phenotypes of DKO gene‐edited CAR T‐19 cells (n = 3 different donors in three independent experiments). (C) Representative HLA‐ABC expression in DKO gene‐edited CAR T‐19 cells. Gates were established by using FMO controls (HLA‐ABC). (D) Representative HLA‐E expression in DKO gene‐edited CAR T‐19 cells. Gates were established by using FMO controls (HLA‐E). (E) Representative HLA‐G expression in DKO gene‐edited CAR T‐19 cells. Gates were established by using FMO controls (HLA‐G). (F) CD107a expression in DKO gene‐edited CAR T‐19 cells after cocultured with CD19+ Raji cells (human Burkitt's lymphoma cell line) and CD19− K562 cells (human chronic myelogenous leukemia cell line) at an effector‐to‐target ratio of 1:1 for 4 h (n = 3 different donors in three independent experiments. **P < 0.01, ***P < 0.001, t‐test, GraphPad Prism version 5).